Multiple single cell studies (Menon et al., 2020; Latt et al., 2022) have identified specific markers such as α-2 macroglobulin (A2M), elevated glomerular endothelial cell score and loss of canonical podocyte markers in patients with FSGS compared to patients with MCD. This evidence concerns the gene A2M and focal segmental glomerulosclerosis.